Announcements Trials
Browse Landscape

Status

Unknown 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 6Observational 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 2934Neoplasms 174Lung Neoplasms 149Prostatic Neoplasms 116Ovarian Neoplasms 113Colorectal Neoplasms 106Triple Negative Breast Neoplasms 98Colonic Neoplasms 91Neoplasm Metastasis 74Melanoma 66Carcinoma, Non-Small-Cell Lung 64Pancreatic Neoplasms 63Carcinoma, Intraductal, Noninfiltrating 60Stomach Neoplasms 54Head and Neck Neoplasms 47Breast Cancer Female 45Lymphedema 42Uterine Cervical Neoplasms 40Breast Carcinoma In Situ 35Esophageal Neoplasms 34Cardiotoxicity 34Urinary Bladder Neoplasms 33Motor Activity 33Lymphoma 33Endometrial Neoplasms 33Breast Diseases 33Fatigue 30Rectal Neoplasms 28Breast Neoplasms, Male 28Multiple Myeloma 27

Interventions

palbociclib 1Fulvestrant 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × HER2-positive Metastatic Breast Cancer × Breast × Clear all
NCT06551116 2026-04-07

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Abramson Cancer Center at Penn Medicine

Recruiting
200 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT06305702 2024-03-12

Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

Liaoning Cancer Hospital & Institute

Completed
500 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT04778982 2023-07-17

Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated
4 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT05188495 2022-01-12

HELP

Peking University Cancer Hospital & Institute

Unknown
60 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡